Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus CHOP in First-line PTCL
NCT03542266Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in peripheral T-cell lymphoma (PTCL), sponsored by Weill Cornell Medicine. Primary endpoint: Complete Response Rate at 18 weeks. Started Jun 2018; status: completed.
02
Drugs
azacitidine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03542266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542266.